Now showing items 1-10 of 31
Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.
(Cancer Prev Res (Phila), 2008-07)
Chemoprevention agents are an emerging new scientific area that holds out the promise of delaying or avoiding a number of common cancers. These new agents face significant scientific, regulatory, and economic barriers, however, ...
Follow-on biologics: data exclusivity and the balance between innovation and competition
(Nature Reviews Drug Discovery, 2008-06)
Generic Competition in the U.S. Pharmaceutical Industry
(International Journal of the Economics of Business, 2006-02)
Do faster food and drug administration drug reviews adversely affect patient safety? An analysis of the 1992 prescription drug user fee act
(Journal of Law and Economics, 2008-05-01)
Food and Drug Administration (FDA) review times have significantly declined under the user-fee regime. This situation has provoked concerns that drug safety has been adversely affected. Combining information from several ...
The cost of biopharmaceutical R&D: Is biotech different?
(Managerial and Decision Economics, 2007-06-01)
The costs of developing the types of new drugs that have been pursued by traditional pharmaceutical firms have been estimated in a number of studies. However, similar analyses have not been published on the costs of developing ...
Should the patent system for new medicines be abolished?
(Clin Pharmacol Ther, 2007-11)
Are the Economics of Pharmaceutical R&D Changing? Productivity, Patents and Political Pressures
Pharmaceutical R&D competition in the 1980s and 1990s was characterized by rising R&D expenditures, favorable returns to innovators, and the introduction of many new classes of drugs with high social benefits. However in ...
How did the 2003 prescription drug re-importation bill pass the house?
(Economics and Politics, 2006-03-01)
We examine the major interest groups in the debate over allowing the re-importation of prescription drugs by utilizing a logit model and instrumental variables. Consistent with political support approach, the evidence suggests ...
Increasing R&D Incentives for Neglected Diseases: Lessons from the Orphan Drug Act
(International Public Goods And Transfer Of Technology Under A Globalized Intellectual Property Regime, 2005)
Patents and New Product Development in the Pharmaceutical and Biotechnology Industry
(The Georgetown Public Policy Review, 2003-03)